Deepeye Medical builds an AI-based software platform that analyzes 3D eye tomography to generate data-driven, personalized treatment suggestions for age-related macular degeneration (AMD). Its algorithm was trained on hundreds of thousands of retinal scans and aims to assess disease activity and progression to help optimize therapy intervals and support patient education. The software is intended to complement clinical expertise and provide a one-click, patient-oriented therapy decision aid by 2024. The company reports collaborations with major pharmaceutical firms including Novartis, Bayer and Roche and is used by companies and physicians to gain insights from therapy data. Deepeye Medical was founded in 2021 and is based in Munich/Landshut. Financially, the company has secured investor funding plus research and development grants to further develop its platform.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2023